ODI Pharma AB (“ODI” or the “Company”) announces today that the preliminary financial results for the third quarter of fiscal year...

ODI Pharma AB (“ODI” or the “Company”) hereby present an updated overview of its market position and the latest trends observed in the...

ODI Pharma AB (“ODI” or the “Company”) hereby publishes its half-year report for the period July – December 2023. The report is available...

ODI Pharma AB (”ODI Pharma” eller ”Bolaget”) har idag utsett Pareto Securities till likviditetsgarant för Bolagets aktie som är upptagen...

ODI Pharma AB (“ODI Pharma” or the “Company”) has today appointed Pareto Securities as the liquidity guarantor for the Company's shares,...

This is an unofficial translation of a notice to the Annual General Meeting in ODI Pharma AB (publ), originally drafted in Swedish. In...

Idag den 15 december 2023 hölls årsstämma i ODI Pharma AB (publ). Nedan följer en sammanfattning av de beslut som fattades. Samtliga...

ODI Pharma AB (“ODI” or the “Company”) announces today the sale of the skincare brand kandol. to Niclas Kappelin. The transaction, valued...

The correction refers to the completion of the auditor's remark and ODI Pharma's comment which is now included in the press release. The...

Rättelsen avser komplettering av revisorns anmärkning och ODI Pharmas kommentar som nu finns inkluderat i pressmeddelandet. Bifogad...

ODI Pharma AB (“ODI” or the “Company”) hereby publishes its interim report for the period July 2023 – September 2023. The report is...

The Board of Directors and the Chief Executive Officer of ODI Pharma AB (“ODI Pharma”) hereby publishes the annual report for the fiscal...

Styrelsen och verkställande direktören för ODI Pharma AB (”ODI Pharma”) publicerar härmed årsredovisningen för räkenskapsåret 2022/2023....

ODI Pharma AB (“ODI” or the “Company”) stated in its year-end report that the interim report for the first quarter of 2023/2024 and the...

The shareholders of ODI Pharma AB (publ), 559223–1392, are hereby invited to attend the Annual General Meeting on Friday, 15th of...

Aktieägarna i ODI Pharma AB (publ), 559223–1392, kallas härmed till årsstämma fredagen den 15 december 2023 kl. 10.30 i bolagets lokaler...

ODI Pharma AB (“ODI” or the “Company”) hereby publishes its year-end report for the period July 2022 – June 2023. The report is available...

ODI Pharma AB (“ODI” or “the Company”) hereby announces that the Company has entered through its Polish subsidiary into a collaboration...

ODI Pharma AB (“ODI” or “the Company”) hereby announces that the Company has secured loan financing of EUR 350,000 from an external...

ODI Pharma AB (“ODI” or the “Company”) hereby publishes its interim report for the period July 2022 – March 2023. The report is available...